Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice

Cancer Prevention Research

Volumn 2, Issue 9, 2009, Pages 792-799

  Romero, Iris L ^a   Gordon, Ilyssa O ^a   Jagadeeswaran, Sujatha ^a   Mui, Keeley L ^a   Lee, Woo Seok ^a   Dinulescu, Daniela M ^b   Krausz, Thomas N ^a   Kim, Helen H ^a   Gilliam, Melissa L ^a   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; GELATINASE A; GONADORELIN AGONIST; LEUPRORELIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; CRE RECOMBINASE; ESTROGEN; GONADORELIN; GONADOTROPIN; INTEGRASE; KRAS2 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; PTEN PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIOID CARCINOMA; ENZYME ACTIVITY; FEMALE; GENETIC ENGINEERING; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; CANCER INVASION; DISEASE MODEL; DRUG POTENTIATION; ENZYME IMMUNOASSAY; ENZYMOLOGY; METABOLISM; MOUSE MUTANT; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CONTRACEPTIVES, ORAL, SYNTHETIC; DISEASE MODELS, ANIMAL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; IMMUNOENZYME TECHNIQUES; INTEGRASES; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NORETHINDRONE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; TUMOR CELLS, CULTURED;

EID: 70449727104     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0236     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-1639 (Pubitemid 41540458)
3. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998;2:i-iv, 1-84. (Pubitemid 28166176)
4. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-265 (Pubitemid 35222295)
5. Rosenberg L, Palmer JR, Zauber AG, et al. A casecontrol study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654-661 (Pubitemid 24121274)
6. Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 2008;19:237-243 (Pubitemid 351253010)
7. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007; 166:894-901.
8. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-314
9. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
10. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721 (Pubitemid 14232385)
11. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-1950 (Pubitemid 27200378)
12. McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ. Effects of progesterone on ovarian tumorigenesis in xenografted mice. Cancer Lett 2005;221:49-53.
13. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11:63-70. (Pubitemid 40215839)
14. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-1397 (Pubitemid 36348722)
15. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-333 (Pubitemid 46518315)
16. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18 Suppl 2:S19-32.
17. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-2097 (Pubitemid 28232892)
18. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-2106 (Pubitemid 32545195)
19. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer riskby histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-638
20. Lesche R, Groszer M, Gao J, et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002;32:148-149 (Pubitemid 34211723)
21. Crickard K, Crickard U, Yoonessi M. Human ovarian carcinoma cells maintained on extracellular matrix versus plastic. Cancer Res 1983;43:2762-2767 (Pubitemid 13100544)
22. A EM. Isolation and propagation of mouse embryonic fibroblasts and preparation of mouse embryonic feeder layer cells. Curr Protoc Stem Cell Biol 2007. Chapter 1:Unit1C.3.
23. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-2404
24. Lengyel E, Ried S, Heiss MM, Jager C, Schmitt M, Allgayer H. Ras regulation of urokinase-type plasminogen activator. Methods Enzymol 2001; 333:105-116 (Pubitemid 32507302)
25. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-1679 (Pubitemid 46383393)
26. Oberholzer M, Ostreicher M, Christen H, Bruhlmann M. Methods in quantitative image analysis. Histochem Cell Biol 1996;105:333-355
27. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-1714
28. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-1379 (Pubitemid 351500430)
29. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer riskas sociated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009;115:531-539
30. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-276
31. Kim JH, Park DC, Kim JW, et al. Antitumor effect of GnRH agonist in epithelial ovarian cancer. Gynecol Oncol 1999;74:170-180
32. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006;66: 10902-10910
33. Armaiz-Pena GN, Mangala LS, Spannuth WA, et al. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 2009;15:2971-2978
34. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-4041 (Pubitemid 47105962)
35. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007;67:2408-2413 (Pubitemid 46548923)
36. Zou DM, Brewer M, Garcia F, et al. Cactus pear: a natural product in cancer chemoprevention. Nutr J 2005;4:25. (Pubitemid 41426874)
37. Zou C, Brewer M, Cao X, et al. Antitumor activity of 4-(N-hydroxyphenyl) retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts. Gynecol Oncol 2007;107:441-449 (Pubitemid 350167464)
38. Song Y, Wilkins P, Hu W, et al. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 2007;406:427-436 (Pubitemid 47425449)
39. Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor γ ligand, on the growth of human ovarian cancers. Cancer 2007;110:791-800. (Pubitemid 47257656)
40. De Palo G, Mariani L, Camerini T, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002;86:24-27
41. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-748
42. Kelloff GJ, Sigman CC, Contag CH. Early detection of oral neoplasia: watching with new eyes. Cancer Prev Res 2009;2:405-408